Plantar fasciopathy

Indication

Plantar fasciopathy is the leading cause of inferior heel pain in adults, typically managed non-operatively for at least 6–12 months before surgery is considered. The decision point that divides surgeons is whether to escalate from load-management and orthoses to injection-based or energy-based modalities, and — if those fail — whether to pursue soft-tissue release (endoscopic fasciotomy) or address proximal biomechanics via gastrocnemius recession.

The techniques

• Corticosteroid injection (CSI): peri-fascial or intralesional depot steroid, usually under ultrasound guidance, aimed at acute inflammatory flare.
• Extracorporeal shockwave therapy (ESWT): focused or radial acoustic pulses delivered in 3–5 weekly sessions to the medial calcaneal tubercle or myofascial referral zones.
• Platelet-rich plasma (PRP): autologous platelet concentrate injected into the plantar fascia origin, often with needling/fenestration.
• Gastrocnemius recession: proximal medial gastrocnemius lengthening (open or endoscopic) to reduce forefoot load in patients with isolated gastrocnemius contracture.
• Endoscopic plantar fasciotomy: partial (50–75 %) release of the central band via two portals under direct visualization.

What the evidence says

ESWT shows consistent short-term pain reduction versus placebo or conservative care in multiple meta-analyses (focal ESWT VAS −2.8; radial ESWT VAS −3.0) [1] and remains the only modality with statistically significant medium- and long-term benefit in a large network meta-analysis (MD −0.97 at 3–6 mo; −2.49 at >12 mo) [2]. However, a well-powered sham-controlled RCT found no difference between radial ESWT plus orthoses and orthoses alone at 6 months (−0.02, 95 % CI −1.01 to 0.96) [3]. PRP outperforms CSI for VAS in open-label trials (SMD 1.08) [4] and versus placebo (MD −3.76) [5], but this superiority disappears in double-blind designs (VAS MD 0.15, p=0.72) [5]. ESWT is superior to CSI at 3 and 6 months for pain (SMD −0.6 and −0.81), fascia thickness (SMD −0.4), and function (SMD 0.27 and 0.67) [6]. Gastrocnemius recession yields a weighted mean 76 % VAS reduction at 12 months across seven heterogeneous studies (three retrospective series, two RCTs, one comparative cohort) with sural neuritis as the main minor complication [7]. No included source evaluates endoscopic plantar fasciotomy; one comparative study in the recession review used open fasciotomy as the control arm [7]. Plantar fascia rupture is strongly associated with prior CSI (130/138 rupture cases had previous steroid injection) [8].

What members see

How often do you see meaningful relief beyond 6 months after a single CSI course versus repeating injection? For those using PRP, do you observe a clinically relevant gap between open-label and blinded outcomes in your practice? What is your re-operation or persistent-symptom rate after gastrocnemius recession versus endoscopic fasciotomy at 2-year follow-up?

Cost and access

Sources do not provide direct cost comparisons. Cost drivers include: implant/kit expense (PRP preparation kits, ESWT device amortization), theatre time and anaesthesia for recession or fasciotomy, potential second procedure for hardware removal (not applicable here), and advanced imaging (MRI/US) for patient selection. Access to ESWT and PRP varies by hospital purchasing agreements and insurance coverage; recession and fasciotomy require operating-room access and surgical privileging.

Open questions

• Does focused ESWT on proximal myofascial points provide durable advantage over standard calcaneal targeting beyond 4 months [9]?
• What is the comparative efficacy of endoscopic plantar fasciotomy versus gastrocnemius recession in recalcitrant cases with documented gastrocnemius contracture?
• Can a validated clinical decision rule identify patients who benefit from proximal lengthening versus fascial release?
• Does the rupture risk after CSI [8] alter the risk–benefit calculus for early versus late injection?
• What is the optimal sham-controlled trial design to isolate the specific biological effect of PRP from needling and volume effects?

References

9 of 16 papers retrieved for this room are cited above. The search was limited to systematic reviews, meta-analyses and randomised trials in humans, English, 2016 onwards. Query and full result set: research/raw/plantar-fasciopathy.json.

1. 1Efficacy and tolerability of extracorporeal shock wave therapy in patients with plantar fasciopathy: a systematic review with meta-analysis and meta-regression. Eur J Phys Rehabil Med 2024 · PMID 39257331 Systematic Review, Meta-Analysis
2. 2Effects of therapeutic interventions on pain due to plantar fasciitis: A systematic review and meta-analysis. Clin Rehabil 2023 · PMID 36571559 Meta-Analysis, Systematic Review
3. 3Is radial extracorporeal shock wave therapy (rESWT), sham-rESWT or a standardised exercise programme in combination with advice plus customised foot orthoses more effective than advice plus customised foot orthoses alone in the treatment of plantar fasciopathy? A double-blind, randomised, sham-controlled trial. Br J Sports Med 2024 · PMID 38904119 Randomized Controlled Trial
4. 4Platelet rich plasma therapy versus other modalities for treatment of plantar fasciitis: A systematic review and meta-analysis. Foot Ankle Surg 2024 · PMID 38395675 Systematic Review, Meta-Analysis
5. 5Outcomes of platelet-rich plasma for plantar fasciopathy: a best-evidence synthesis. J Orthop Surg Res 2020 · PMID 32958046 Systematic Review
6. 6Efficacy of extracorporeal shockwave therapy, compared to corticosteroid injections, on pain, plantar fascia thickness and foot function in patients with plantar fasciitis: A systematic review and meta-analysis. Clin Rehabil 2024 · PMID 38738305 Meta-Analysis, Systematic Review
7. 7Gastrocnemius Recession in Recalcitrant Plantar Fasciitis: A Systematic Review. J Foot Ankle Surg 2022 · PMID 34838458 Systematic Review
8. 8Ruptures of the Plantar Fascia: A Systematic Review of the Literature. Foot Ankle Spec 2022 · PMID 33307799 Systematic Review
9. 9Myofascial points treatment with focused extracorporeal shock wave therapy (f-ESWT) for plantar fasciitis: an open label randomized clinical trial. Eur J Phys Rehabil Med 2022 · PMID 34786906 Randomized Controlled Trial

Back to the comparisons